| | |
| Clinical data | |
|---|---|
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C11H12O2 |
| Molar mass | 176.215 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| | |
Centalun was developed by Boehringer Ingelheim in 1962 [1] and is a psycholeptic drug with hypnotic and sedative effects, via allosteric agonism of the GABAA receptor. [2] It was previously used for sedation in medical procedures such as surgery, [3] orthopedics [4] and gynecology, [5] although it is no longer in clinical use. Despite its history of clinical use, centalun was never incorporated into the CSA and therefore remains unregulated as a drug of abuse.